Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus.

Burgess HM, Pourchet A, Hajdu CH, Chiriboga L, Frey AB, Mohr I.

Mol Ther Oncolytics. 2018 Jan 31;8:71-81. doi: 10.1016/j.omto.2018.01.001. eCollection 2018 Mar 30.

2.

The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8+ T-cell Function.

Frey AB.

Cancer Immunol Res. 2017 Oct;5(10):920-928. doi: 10.1158/2326-6066.CIR-17-0187. Epub 2017 Sep 5.

3.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A, Ostrand-Rosenberg S, Rodriguez PC, Sica A, Umansky V, Vonderheide RH, Gabrilovich DI.

Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150. Review.

4.

Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets.

Moogk D, Zhong S, Yu Z, Liadi I, Rittase W, Fang V, Dougherty J, Perez-Garcia A, Osman I, Zhu C, Varadarajan N, Restifo NP, Frey AB, Krogsgaard M.

J Immunol. 2016 Jul 15;197(2):644-54. doi: 10.4049/jimmunol.1600178. Epub 2016 Jun 6.

5.

CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.

Pourchet A, Fuhrmann SR, Pilones KA, Demaria S, Frey AB, Mulvey M, Mohr I.

EBioMedicine. 2016 Jan 19;5:59-67. doi: 10.1016/j.ebiom.2016.01.022. eCollection 2016 Mar.

6.

Identification of Candidate Tolerogenic CD8(+) T Cell Epitopes for Therapy of Type 1 Diabetes in the NOD Mouse Model.

Yu C, Burns JC, Robinson WH, Utz PJ, Ho PP, Steinman L, Frey AB.

J Diabetes Res. 2016;2016:9083103. doi: 10.1155/2016/9083103. Epub 2016 Mar 16.

7.

Suppression of T cell responses in the tumor microenvironment.

Frey AB.

Vaccine. 2015 Dec 16;33(51):7393-7400. doi: 10.1016/j.vaccine.2015.08.096. Epub 2015 Sep 25. Review.

PMID:
26403368
8.

Impact of immediate evaluation of touch imprint cytology from computed tomography guided core needle biopsies of mass lesions: Single institution experience.

Moghadamfalahi M, Podoll M, Frey AB, Alatassi H.

Cytojournal. 2014 Jun 12;11:15. doi: 10.4103/1742-6413.134437. eCollection 2014.

9.

Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.

Monu NR, Frey AB.

Immunol Invest. 2012;41(6-7):595-613. doi: 10.3109/08820139.2012.673191. Review.

10.

Neuropilin 1 is expressed on thymus-derived natural regulatory T cells, but not mucosa-generated induced Foxp3+ T reg cells.

Weiss JM, Bilate AM, Gobert M, Ding Y, Curotto de Lafaille MA, Parkhurst CN, Xiong H, Dolpady J, Frey AB, Ruocco MG, Yang Y, Floess S, Huehn J, Oh S, Li MO, Niec RE, Rudensky AY, Dustin ML, Littman DR, Lafaille JJ.

J Exp Med. 2012 Sep 24;209(10):1723-42, S1. Epub 2012 Sep 10.

11.

MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells.

Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S, Barilla R, Zambirinis CP, Fallon NC, Rehman A, Pylayeva-Gupta Y, Badar S, Hajdu CH, Frey AB, Bar-Sagi D, Miller G.

J Exp Med. 2012 Aug 27;209(9):1671-87. doi: 10.1084/jem.20111706. Epub 2012 Aug 20.

12.

Dendritic cell populations with different concentrations of lipid regulate tolerance and immunity in mouse and human liver.

Ibrahim J, Nguyen AH, Rehman A, Ochi A, Jamal M, Graffeo CS, Henning JR, Zambirinis CP, Fallon NC, Barilla R, Badar S, Mitchell A, Rao RS, Acehan D, Frey AB, Miller G.

Gastroenterology. 2012 Oct;143(4):1061-72. doi: 10.1053/j.gastro.2012.06.003. Epub 2012 Jun 12.

13.

Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells.

Vazquez-Cintron EJ, Monu NR, Burns JC, Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB.

PLoS One. 2012;7(5):e36101. doi: 10.1371/journal.pone.0036101. Epub 2012 May 2.

14.

The detection and differentiation of methicillin-resistant and methicillin-susceptible Staphylococcus aureus endocarditis by using the BD GeneOhm StaphSR Assay.

Frey AB, Wilson DA, LaSalvia MM, Tan CD, Rodriguez ER, Shrestha NK, Hall GS, Procop GW.

Am J Clin Pathol. 2011 Nov;136(5):686-9. doi: 10.1309/AJCP9L3BHHGUAQUD.

PMID:
22031305
15.

Dendritic cells promote pancreatic viability in mice with acute pancreatitis.

Bedrosian AS, Nguyen AH, Hackman M, Connolly MK, Malhotra A, Ibrahim J, Cieza-Rubio NE, Henning JR, Barilla R, Rehman A, Pachter HL, Medina-Zea MV, Cohen SM, Frey AB, Acehan D, Miller G.

Gastroenterology. 2011 Nov;141(5):1915-26.e1-14. doi: 10.1053/j.gastro.2011.07.033. Epub 2011 Jul 27.

16.

Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Vazquez-Cintron EJ, Monu NR, Frey AB.

J Immunol. 2010 Dec 15;185(12):7133-40. doi: 10.4049/jimmunol.1001157. Review.

17.

In hepatic fibrosis, liver sinusoidal endothelial cells acquire enhanced immunogenicity.

Connolly MK, Bedrosian AS, Malhotra A, Henning JR, Ibrahim J, Vera V, Cieza-Rubio NE, Hassan BU, Pachter HL, Cohen S, Frey AB, Miller G.

J Immunol. 2010 Aug 15;185(4):2200-8. doi: 10.4049/jimmunol.1000332. Epub 2010 Jul 16.

18.

Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor.

Connolly MK, Mallen-St Clair J, Bedrosian AS, Malhotra A, Vera V, Ibrahim J, Henning J, Pachter HL, Bar-Sagi D, Frey AB, Miller G.

J Leukoc Biol. 2010 Apr;87(4):713-25. doi: 10.1189/jlb.0909607. Epub 2009 Dec 30.

19.

In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha.

Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A, Pachter HL, Bar-Sagi D, Frey AB, Miller G.

J Clin Invest. 2009 Nov;119(11):3213-25. doi: 10.1172/JCI37581. Epub 2009 Oct 12.

20.

Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes.

Nonaka K, Saio M, Suwa T, Frey AB, Umemura N, Imai H, Ouyang GF, Osada S, Balazs M, Adany R, Kawaguchi Y, Yoshida K, Takami T.

J Leukoc Biol. 2008 Sep;84(3):679-88. doi: 10.1189/jlb.1107729. Epub 2008 Jun 19.

PMID:
18566103
21.

Signaling defects in anti-tumor T cells.

Frey AB, Monu N.

Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x. Review.

22.
23.

Protein kinase Cdelta regulates antigen receptor-induced lytic granule polarization in mouse CD8+ CTL.

Ma JS, Monu N, Shen DT, Mecklenbräuker I, Radoja N, Haydar TF, Leitges M, Frey AB, Vukmanovic S, Radoja S.

J Immunol. 2007 Jun 15;178(12):7814-21.

24.
25.

TNF expressed by tumor-associated macrophages, but not microglia, can eliminate glioma.

Nakagawa J, Saio M, Tamakawa N, Suwa T, Frey AB, Nonaka K, Umemura N, Imai H, Ouyang GF, Ohe N, Yano H, Yoshimura S, Iwama T, Takami T.

Int J Oncol. 2007 Apr;30(4):803-11.

PMID:
17332918
26.
27.

T-cell receptor signaling events triggering granule exocytosis.

Radoja S, Frey AB, Vukmanovic S.

Crit Rev Immunol. 2006;26(3):265-90. Review.

PMID:
16928189
28.

Defective adhesion in tumor infiltrating CD8+ T cells.

Koneru M, Monu N, Schaer D, Barletta J, Frey AB.

J Immunol. 2006 May 15;176(10):6103-11.

29.

Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.

Frey AB, Monu N.

J Leukoc Biol. 2006 Apr;79(4):652-62. Epub 2006 Jan 13. Review.

PMID:
16415165
30.

Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.

Koneru M, Schaer D, Monu N, Ayala A, Frey AB.

J Immunol. 2005 Feb 15;174(4):1830-40.

31.

Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Saio M, Teicher M, Campbell G, Feiner H, Delgado Y, Frey AB.

Clin Exp Metastasis. 2004;21(3):243-9.

PMID:
15387374
32.

The role of fibroblasts in thymocyte-positive selection.

Lilić M, Santori FR, Neilson EG, Frey AB, Vukmanović S.

J Immunol. 2002 Nov 1;169(9):4945-50.

33.
34.
37.

Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.

Straubinger RK, Dharma Rao T, Davidson E, Summers BA, Jacobson RH, Frey AB.

Vaccine. 2001 Oct 12;20(1-2):181-93.

PMID:
11567763
38.
39.

Type I IFN modulates innate and specific antiviral immunity.

Durbin JE, Fernandez-Sesma A, Lee CK, Rao TD, Frey AB, Moran TM, Vukmanovic S, García-Sastre A, Levy DE.

J Immunol. 2000 Apr 15;164(8):4220-8.

40.

Distinct requirements for IFNs and STAT1 in NK cell function.

Lee CK, Rao DT, Gertner R, Gimeno R, Frey AB, Levy DE.

J Immunol. 2000 Oct 1;165(7):3571-7.

42.

Mice bearing late-stage tumors have normal functional systemic T cell responses in vitro and in vivo.

Radoja S, Rao TD, Hillman D, Frey AB.

J Immunol. 2000 Mar 1;164(5):2619-28.

43.

NKT cell cytokine imbalance in murine diabetes mellitus.

Frey AB, Rao TD.

Autoimmunity. 1999;29(3):201-14.

PMID:
10433100
44.

Protection from Lyme neuroborreliosis in nonhuman primates with a multiantigenic vaccine.

Pachner AR, Delaney E, Zhang WF, O'Neill T, Major E, Frey AB, Davidson E.

Clin Immunol. 1999 Jun;91(3):310-3.

PMID:
10370376
46.

Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Yu J, Caragine T, Chen S, Morgan BP, Frey AB, Tomlinson S.

Clin Exp Immunol. 1999 Jan;115(1):13-8.

47.

Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes.

Lopez CB, Rao TD, Feiner H, Shapiro R, Marks JR, Frey AB.

Cell Immunol. 1998 Dec 15;190(2):141-55.

PMID:
9878115
48.

Rat NKR-P1+ CD3+ T cells: selective proliferation in interleukin-2, diverse T-cell-receptor-Vbeta repertoire and polarized interferon-gamma expression.

Badovinac V, Boggiano C, Trajković V, Frey AB, Vujanović NL, Gold DP, Mostarica-Stojković M, Vukmanović S.

Immunology. 1998 Sep;95(1):117-25.

49.

Supplemental Content

Support Center